keyword
MENU ▼
Read by QxMD icon Read
search

abatacept

keyword
https://www.readbyqxmd.com/read/29329602/abatacept-used-in-combination-with-non-methotrexate-disease-modifying-antirheumatic-drugs-a-descriptive-analysis-of-data-from-interventional-trials-and-the-real-world-setting
#1
Rieke Alten, Harald Burkhardt, Eugen Feist, Klaus Krüger, Juergen Rech, Andrea Rubbert-Roth, Reinhard E Voll, Yedid Elbez, Christiane Rauch
BACKGROUND: Methotrexate (MTX) remains the anchor drug in rheumatoid arthritis (RA) treatment, but is poorly tolerated or contraindicated in some patients. There is a wealth of data supporting the use of abatacept in combination with MTX, but data on alternative conventional synthetic disease-modifying antirheumatic drug (csDMARD) combinations with abatacept are scarce. METHODS: In this post-hoc exploratory analysis, efficacy and safety data were extracted from abatacept RA studies in which combination with csDMARDs other than MTX was permitted: three interventional trials (ATTAIN, ASSURE, and ARRIVE) and one real-world study (ACTION)...
January 2, 2018: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29321374/selective-cd28-blockade-attenuates-ctla-4-dependent-cd8-memory-t-cell-effector-function-and-prolongs-graft-survival
#2
Danya Liu, I Raul Badell, Mandy L Ford
Memory T cells pose a significant problem to successful therapeutic control of unwanted immune responses during autoimmunity and transplantation, as they are differentially controlled by cosignaling receptors such as CD28 and CTLA-4. Treatment with abatacept and belatacept impede CD28 signaling by binding to CD80 and CD86, but they also have the unintended consequence of blocking the ligands for CTLA-4, a process that may inadvertently boost effector responses. Here, we show that a potentially novel anti-CD28 domain antibody (dAb) that selectively blocks CD28 but preserves CTLA-4 coinhibition confers improved allograft survival in sensitized recipients as compared with CTLA-4 Ig...
January 11, 2018: JCI Insight
https://www.readbyqxmd.com/read/29313055/abatacept-improves-skin-score-and-reduces-lesions-in-patients-with-localized-scleroderma-a-case-series
#3
Simon Wehner Fage, Kristian Bakke Arvesen, Anne Braae Olesen
No abstract text is available yet for this article.
January 9, 2018: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/29303709/cost-effectiveness-of-early-treatment-of-acpa-positive-rheumatoid-arthritis-patients-with-abatacept
#4
Aljoscha S Neubauer, Christof Minartz, Kirsten H Herrmann, Christoph G O Baerwald
OBJECTIVES: Studies have reported that the presence of elevated anti-citrullinated protein antibodies (ACPA)/RF levels, together with joint erosions, is associated with higher disease burden in terms of disability and mortality in rheumatoid arthritis (RA). Abatacept has been shown to be effective in this patient population with favourable comparative data against adalimumab. However, few studies have investigated the cost-effectiveness of abatacept in this population to similar treatments such as TNFs...
December 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29303704/golimumab-in-refractory-uveitis-associated-to-juvenile-idiopathic-arthritis-multicentre-study-of-7-cases-and-literature-review
#5
REVIEW
Natalia Palmou-Fontana, Vanesa Calvo-Río, José Luis Martín-Varillas, Carlos Fernández-Díaz, Marina Mesquida, Alfredo Adán, María Victoria Hernández, Miguel Cordero-Coma, Olga Maiz Alonso, David Díaz-Valle, Carlos Fernández-Cid, Oscar Ruiz-Moreno, José Luis Hernández, Miguel Angel González-Gay, Ricardo Blanco
OBJECTIVES: To assess the efficacy of golimumab (GLM), a fully humanised anti-TNF-α monoclonal antibody, in refractory juvenile idiopathic arthritis (JIA)-associated uveitis. METHODS: This was a multicentre study of JIA-associated uveitis refractory to standard synthetic immunosuppressive drugs and in most cases to other anti-TNF-α agents. Results were expressed as mean±standard deviation or as median (range or interquartile range). The Wilcoxon signed-rank test was used to compare continuous variables...
December 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29285605/comparative-effectiveness-of-abatacept-apremilast-secukinumab-and-ustekinumab-treatment-of-psoriatic-arthritis-a-systematic-review-and-network-meta-analysis
#6
REVIEW
P Kawalec, P Holko, P Moćko, A Pilc
To assess the comparative effectiveness and safety of novel biologic therapies in psoriatic arthritis (PsA) and to establish the position of the non-anti-tumor necrosis factor α (TNF-α) biologic drugs in the treatment regimen of the disease. A systematic review and network meta-analysis (NMA) was conducted according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) requirements. Two investigators identified the studies, abstracted data, and assessed the risk of bias independently...
December 28, 2017: Rheumatology International
https://www.readbyqxmd.com/read/29278210/biologics-in-inflammatory-and-immunomediated-arthritis
#7
Michele Maria Luchetti, Devis Benfaremo, Armando Gabrielli
BACKGROUND: Biologic drugs, introduced in clinical practice almost twenty years ago, represent nowadays a prominent treatment option in patients with chronic inflammatory arthritis, such as Rheumatoid Arthritis, Psoriatic Arthritis and Spondyloarthritis, that include ankylosing spondylitis and non-radiographic axial spondyloarthritis. METHODS: Several compounds targeting different pathways have been marketed and approved for the treatment of inflammatory arthritis, with a significant impact on the clinical outcomes and the natural history of the diseases...
December 26, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/29259723/effects-of-ctla4-ig-on-human-monocytes
#8
Toshihiro Tono, Satoko Aihara, Takayuki Hoshiyama, Yoshiyuki Arinuma, Tatsuo Nagai, Shunsei Hirohata
Background: Abatacept, a CTLA4-Ig fusion protein attenuates T cell activation by inhibiting the CD80/86-CD28 costimulatory pathway that is required for the proper T cell activation and thus displays beneficial effects in the treatment of rheumatoid arthritis (RA). Although some studies have disclosed the in vitro effects of this biological agent on the immune-competent cells, the precise mechanisms of action in RA still remain unclear. The current studies were therefore undertaken to explore the effects of abatacept on monocytes in detail...
2017: Inflammation and Regeneration
https://www.readbyqxmd.com/read/29249233/abatacept-efficacy-in-steroid-resistant-minimal-change-disease-revealed-by-the-speed-of-proteinuria-reduction-after-the-start-of-abatacept%C3%A2
#9
David Dado, Samir Parikh, Isabelle Ayoub, Brad Rovin, Tibor Nadasdy, Lee Hebert
A unique characteristic of the response of minimal-change disease (MCD) or focal and segmental glomerulosclerosis (FSGS) to steroid therapy is that the remission of proteinuria occurs quickly, for example, within 4 - 6 weeks of the onset of steroid therapy, even in those with severe nephrotic syndrome. Remission of proteinuria in MCD and FSGS can also occur spontaneously (not steroid induced). However, spontaneous remission usually proceeds over several months or longer. Recently, there have been several reports that abatacept can induce proteinuria remission in MCD and FSGS...
December 18, 2017: Clinical Nephrology
https://www.readbyqxmd.com/read/29247389/degree-of-prescriber-s-knowledge-about-variability-in-biological-drugs-innovators-in-manufacturing-process
#10
Lucía Jiménez-Pichardo, Rocío Gázquez-Pérez, Jesús Francisco Sierra-Sánchez
PURPOSE: The purpose of the study is to analyse the degree of prescribers' knowledge about the regulation and variability in manufacturing processes (MP) in bio-drugs "innovators" (BI). METHODS: For each selected drugs, the date of authorization by the European Medicines Agency, time elapsed until the first change, total number of changes and annual rate of change (ARC) were recorded. A survey was designed with 4 parts: (a) identifying the BI prescribed; (b) knowledge of the number and ARC of each BI during its MP; (c) knowledge of comparability requirement of BI before or after the MP; (d) evaluating the utility of the information in the survey...
December 15, 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29237621/patient-characteristics-influence-the-choice-of-biological-drug-in-ra-and-will-make-non-tnfi-biologics-appear-more-harmful-than-tnfi-biologics
#11
Thomas Frisell, Eva Baecklund, Karin Bengtsson, Daniela Di Giuseppe, Helena Forsblad-d'Elia, Johan Askling
OBJECTIVES: With the wide range of biological disease-modifying anti-rheumatic drugs (bDMARDs) available for treating rheumatoid arthritis (RA), and limited evidence to guide the choice for individual patients, we wished to evaluate whether patient characteristics influence the choice of bDMARD in clinical practice, and to quantify the extent to which this would bias direct comparisons of treatment outcome. METHODS: Register-based study of all Swedish patients with RA initiating necrosis factor inhibitor (TNFi), rituximab, abatacept or tocilizumab in 2011-2015 as their first bDMARD (n=6481), or after switch from TNFi as first bDMARD (n=2829)...
December 13, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29214037/correlation-of-hypogammaglobulinaemia-with-proteinuria-and-the-relationship-between-hypogammaglobulinaemia-and-infection-in-active-lupus-nephritis
#12
Dawn Elaine Smilek, Noha Lim, Linna Ding, Sara G Murray, Betty Diamond, David Wofsy
Objective: To evaluate hypogammaglobulinaemia and risk of serious infectious adverse events in active lupus nephritis. Methods: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study (ACCESS) compared abatacept with placebo in participants with lupus nephritis undergoing treatment with Euro-Lupus Nephritis low-dose cyclophosphamide. Serum IgG levels were assessed prior to initiation of treatment and throughout the trial. Hypogammaglobulinaemia was defined as IgG <450 mg/dL...
2017: Lupus Science & Medicine
https://www.readbyqxmd.com/read/29214034/identification-of-biomarkers-of-response-to-abatacept-in-patients-with-sle-using-deconvolution-of-whole-blood-transcriptomic-data-from-a-phase-iib-clinical-trial
#13
Somnath Bandyopadhyay, Sean E Connolly, Omar Jabado, June Ye, Sheila Kelly, Michael A Maldonado, Rene Westhovens, Peter Nash, Joan T Merrill, Robert M Townsend
Objective: To characterise patients with active SLE based on pretreatment gene expression-defined peripheral immune cell patterns and identify clusters enriched for potential responders to abatacept treatment. Methods: This post hoc analysis used baseline peripheral whole blood transcriptomic data from patients in a phase IIb trial of intravenous abatacept (~10 mg/kg/month). Cell-specific genes were used with a published deconvolution algorithm to identify immune cell proportions in patient samples, and unsupervised consensus clustering was generated...
2017: Lupus Science & Medicine
https://www.readbyqxmd.com/read/29205926/a-retrospective-review-of-the-persistence-on-bdmards-prescribed-for-the-treatment-of-rheumatoid-arthritis-in-the-australian-population
#14
Graeme Jones, Stephen Hall, Paul Bird, Geoff Littlejohn, Kathleen Tymms, Peter Youssef, Eric Chung, Rina Barrett, Peter Button
AIM: To describe the persistence of biologic disease modifying anti-rheumatic drugs (bDMARDs) in Australian rheumatoid arthritis (RA) patients, and assess the influence of methotrexate and other conventional DMARD (cDMARD) concomitant medications, and treatment line on bDMARD persistence and glucocorticoids usage. METHOD: RA patients, from the 10% Australian Medicare random sample, aged ≥18 for whom bDMARDs were dispensed were included. Individual sub-cutaneous (SC) anti-tumor necrosis factor-α (anti-TNFα) agents were combined as they were equivalent...
December 5, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/29205904/dosing-down-and-then-discontinuing-biologic-therapy-in-rheumatoid-arthritis-a-review-of-the-literature
#15
REVIEW
Der-Yuan Chen, Chak Sing Lau, Bassel Elzorkany, Ping-Ning Hsu, Sonja Praprotnik, Radu Vasilescu, Lisa Marshall, Lyndon Llamado
AIM: To review the published studies that dose down and then discontinue biologic therapy in patients with rheumatoid arthritis (RA), particularly concerning the criteria for such dosing and the impact on clinical outcomes. METHODS: Published studies conducted in patients with RA that sequentially decreased the dose and then discontinued therapy were included if one or more of the following biologic disease modifying antirheumatic drugs (bDMARDs) was evaluated: abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab, rituximab or tocilizumab...
December 4, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/29204683/wide-difference-in-biologics-usage-and-expenditure-for-the-treatment-of-patients-with-rheumatoid-arthritis-in-each-prefecture-in-japan-analyzed-using-national-database-of-health-insurance-claims-and-specific-health-checkups-of-japan
#16
Yasuyuki Kamata, Seiji Minota
To analyze the biologics usage and expenditure for the treatment of patients with rheumatoid arthritis (RA) in each prefecture throughout Japan using the national open database, the Ministry of Health, Labour and Welfare of Japan disclosed; in Oct 2016, the data of the top 30 most-frequently prescribed drugs during a 1-year period from April 2014 to March 2015 in each prefecture in Japan, along with the patients' age and sex. Seldom-used drugs were excluded. We picked up only biologics for the present study...
December 5, 2017: Rheumatology International
https://www.readbyqxmd.com/read/29197108/refining-a-claims-based-algorithm-to-estimate-biologic-medication-effectiveness-and-cost-per-effectively-treated-patient-with-rheumatoid-arthritis
#17
Ryan A Popp, Karen Rascati, Matthew Davis, Ujas Patel
BACKGROUND: Claims data generally lack information on clinical outcomes. However, a validated, claims-based algorithm for estimating effectiveness of biologic agents in treating rheumatoid arthritis (RA) has recently been developed and applied to various databases. OBJECTIVES: The objectives of the study were to implement a claims-based algorithm in a large nationwide database to estimate medication effectiveness and cost for patients with RA using biologic disease-modifying antirheumatic drugs (DMARDs) and to assess the effect of eliminating one criterion from the algorithm on results...
December 1, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/29177081/impact-of-gender-on-the-response-and-tolerance-to-abatacept-in-patients-with-rheumatoid-arthritis-results-from-the-ora-registry
#18
Cynthia Nourisson, Martin Soubrier, Aurélien Mulliez, Athan Baillet, Thomas Bardin, Alain Cantagrel, Bernard Combe, Maxime Dougados, René-Marc Flipo, Thierry Schaeverbeke, Jean Sibilia, Olivier Vittecoq, Philippe Ravaud, Jacques-Eric Gottenberg, Xavier Mariette, Anne Tournadre
Objective: The impact of gender on the response and tolerance to abatacept was assessed in a large prospective cohort during 2 years of follow-up. Methods: From the 1017 patients included in the Orencia and Rheumatoid Arthritis registry, disease activity was assessed at baseline, 6, 12 and 24 months. The relationship between the European League Against Rheumatism (EULAR) response, Disease Activity Score 28 (DAS28) remission, rate of adverse events and gender was explored in multivariate analysis...
2017: RMD Open
https://www.readbyqxmd.com/read/29161466/treating-early-undifferentiated-arthritis-a-systematic-review-and-meta-analysis-of-direct-and-indirect-trial-evidence
#19
Maria A Lopez-Olivo, Voke Kakpovbia-Eshareturi, Jude des Bordes, Andrea Barbo, Robin Christensen, Maria E Suarez-Almazor
OBJECTIVE: We undertook a systematic review and meta-analysis of direct and indirect trial evidence to evaluate the efficacy of treatments for patients with undifferentiated arthritis (UA). METHODS: We searched four electronic databases from inception to January 2016, clinicaltrials. gov, and bibliographies of relevant articles. Two reviewers independently screened and evaluated the studies. The primary outcome was development of rheumatoid arthritis (RA). RESULTS: Nine studies were included...
November 21, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/29160524/a-fatal-case-of-tuberculous-meningitis-in-a-child-with-juvenile-idiopathic-arthritis-a-diagnostic-challenge
#20
Zumrut Sahbudak Bal, Pinar Yazici, Semra Sen, Cenk Eraslan, Cengiz Cavusoglu, Bulent Karapinar, Fadil Vardar
The prognosis of tuberculous meningitis, a rare form of extrapulmonary tuberculosis, depends on the stage of treatment initiation. We report a fatal case of tuberculous meningitis. The patient had received successive tumor necrosis factor (TNF) antagonists and abatacept to treat juvenile idiopathic arthritis, with negative results for polymerase chain reaction and acid-fast bacilli on smear, had normal cerebrospinal fluid (CSF) adenosine deaminase and glucose levels. Six weeks post-admission, the CSF culture demonstrated Mycobacterium tuberculosis...
September 2017: Revista da Sociedade Brasileira de Medicina Tropical
keyword
keyword
34738
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"